$5650 | Single User
$6650 | Multi User
$8150 | Corporate License
$10000 | Enterprise License

Drug Discovery Services Market by Process (Target Selection, Hit-to-Lead Identification, Lead Optimization), Type (Medicinal Chemistry, Biology Services, DMPK), Drug Type (Small Molecules, Biologics), Therapeutic Areas (Oncology, Neurology) - Forecast to 2022
[Lowest Price Guaranteed: $5,650]

Published by MarketsandMarkets: 27 Oct 2017 | 139339 | In Stock
Related Topics: Bioscience , Healthcare

Introduction

“The drug discovery services market projected to grow at a CAGR of 11.6%.”

The drug discovery services market was valued at USD 8.32 billion in 2017 and expected to grow at a CAGR of 11.6% to reach USD 14.40 billion in 2022. The major factors driving the growth of this market are increasing research and development expenditure, inclination of major pharmaceutical companies towards outsourcing to avoid hurdles, and increasing demand for outsourcing of analytical testing and clinical trial services. However, the high cost involved in drug discovery and development, stringent regulations governing drug discovery, and animal usage are restraining the growth of this market

“The hit-to-lead generation segment is expected to register the highest CAGR during the forecast period.”

On the basis of process, the market is classified into target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. The hit-to-lead identification segment is expected to register the highest growth rate during the forecast period. The growth of this market segment is mainly driven by attributed to the emerging advanced technologies for high-throughput screening (HTS).

“The medicinal chemistry segment to grow at the fastest rate during the forecast period.”

By type, the drug discovery services market is segmented into medicinal chemistry, biology services, and drug metabolism and pharmacokinetics (DMPK). The medicinal chemistry segment is expected to register the highest growth rate during the forecast period. Increasing R&D expenditure, growing number of drug discovery and developmental activities, and increasing inclination of pharmaceutical companies towards outsourcing are among the major factors driving the growth of the medicinal chemistry segment.

“North America to hold the largest share and Asia Pacific is projected to be the fastest-growing regional market during the forecast period.”

Geographically, the drug discovery services market is dominated by North America, followed by Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to command the largest share of the drug discovery services market. The large share of this segment can be attributed to the presence of leading CROs and pharmaceutical companies in this region. The Asia Pacific region is estimated to grow at the fastest rate which can be attributed to less stringent regulations and economical manufacturing costs.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type - Tier 1 – 40%; Tier 2 – 30% and Tier 3 – 30%

• By Designation – C-level – 62%, Director Level – 21%, Others – 17%

• By Region – North America – 50%, Europe – 20%, Asia Pacific – 20% , RoW- 10%

Key players operating in the drug discovery services market include Thermo Fisher Scientific (US), Albany Molecular Research Inc. (AMRI) (US), Charles River Laboratories (US), Evotec (Germany), Domainex (UK), GenScript (US), Covance (US), Selcia (UK), Viva Biotech (China), WuXi AppTec (China), SRI International (US), Pharmaceutical Product Development, LLC (PPD) (US), GVK Biosciences (India), Jubilant Biosys (India), GE Healthcare (US), Merck (Germany), Lonza (Switzerland), Piramal Enterprises (India), Advinus Therapeutics (India), Promega Corporation (US), Syngene International (India), Aurigene (India), Agilent Technologies (US), Ubiquigent (UK), and ChemBridge Corporation (US).

Research Coverage:

The report analyses the drug discovery services market by process, type, drug type, therapeutic area, and region. Apart from a comprehensive geographic product analysis and market sizing, the report also provides the competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the report analyses developments and strategies adopted by key players to maintain and increase their shares in the market. The above-mentioned market research data, market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions to be successful in the market.

Benefits of Buying this Report:

This report will enable both established firms as well as new entrants/smaller firms gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the five strategies mentioned below to strengthen their market shares.

The report provides insights on the following strategies:

• Market Penetration: The report analyzes the drug discovery services market by process, type, drug type, and therapeutic area

• Competitive Assessment: In-depth assessment of the market strategies, and geographic and business segments of the leading players in the drug discovery services market

• Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market

• Market Development: Comprehensive information about emerging markets. This report analyzes the market for various drug discovery services across geographies

• Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the drug discovery services market

Table of Contents
for Drug Discovery Services Market by Process (Target Selection, Hit-to-Lead Identification, Lead Optimization), Type (Medicinal Chemistry, Biology Services, DMPK), Drug Type (Small Molecules, Biologics), Therapeutic Areas (Oncology, Neurology) - Forecast to 2022

  • TABLE OF CONTENTS

    1 INTRODUCTION 16

    1.1 OBJECTIVES OF THE STUDY 16

    1.2 MARKET DEFINITION 16

    1.3 MARKET SCOPE 17

    1.3.1 MARKETS COVERED 17

    1.3.2 YEARS CONSIDERED FOR THE STUDY 18

    1.4 CURRENCY 18

    1.5 LIMITATIONS 18

    1.6 STAKEHOLDERS 18

    2 RESEARCH METHODOLOGY 19

    2.1 RESEARCH DATA 19

    2.2 SECONDARY DATA 20

    2.2.1 KEY DATA FROM SECONDARY SOURCES 20

    2.3 PRIMARY DATA 21

    2.3.1 KEY DATA FROM PRIMARY SOURCES 21

    2.4 MARKET SIZE ESTIMATION 23

    2.4.1 BOTTOM-UP APPROACH 23

    2.4.2 TOP-DOWN APPROACH 24

    2.5 DATA TRIANGULATION 25

    2.6 ASSUMPTIONS FOR THE STUDY 26

    3 EXECUTIVE SUMMARY 27

    4 PREMIUM INSIGHTS 32

    4.1 DRUG DISCOVERY SERVICES MARKET OVERVIEW 32

    4.2 EUROPEAN DRUG DISCOVERY SERVICES MARKET SHARE,

    BY THERAPEUTIC AREA AND COUNTRY 33

    4.3 DRUG DISCOVERY SERVICES MARKET, BY TYPE 34

    4.4 GEOGRAPHICAL SNAPSHOT OF THE DRUG DISCOVERY SERVICES MARKET 35

    5 MARKET OVERVIEW 36

    5.1 INTRODUCTION 36

    5.2 MARKET DYNAMICS 36

    5.2.1 DRIVERS 37

    5.2.1.1 Increasing R&D expenditure 37

    5.2.1.2 Increasing demand for outsourcing analytical testing and clinical trial services 38

    5.2.1.3 Initiatives for research on rare diseases 39

    5.2.1.4 Focus on drug discovery 40

    5.2.2 RESTRAINTS 41

    5.2.2.1 High cost of drug discovery and development 41

    5.2.2.2 Stringent regulations governing drug discovery, and animal usage 42

    5.2.3 OPPORTUNITIES 42

    5.2.3.1 Introduction of advanced technologies 42

    5.2.3.2 Patent expiries to boost the demand for drug discovery 42

    5.2.4 BURNING ISSUES 43

    5.2.4.1 Need for harmonization of regulations, IP rights 43

    6 DRUG DISCOVERY SERVICES MARKET, BY PROCESS 44

    6.1 INTRODUCTION 45

    6.2 TARGET SELECTION 46

    6.3 TARGET VALIDATION 47

    6.4 HIT-TO-LEAD IDENTIFICATION 48

    6.5 LEAD OPTIMIZATION 49

    6.6 CANDIDATE VALIDATION 50

    7 DRUG DISCOVERY SERVICES MARKET, BY TYPE 51

    7.1 INTRODUCTION 52

    7.2 MEDICINAL CHEMISTRY 53

    7.3 BIOLOGY SERVICES 54

    7.4 DRUG METABOLISM AND PHARMACOKINETICS (DMPK) 55

    8 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE 56

    8.1 INTRODUCTION 57

    8.2 SMALL MOLECULES 58

    8.3 BIOLOGICS 59

    9 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA 60

    9.1 INTRODUCTION 61

    9.2 ONCOLOGY 63

    9.3 NEUROLOGY 64

    9.4 CARDIOVASCULAR DISEASES 65

    9.5 RESPIRATORY DISEASES 66

    9.6 DIABETES 67

    9.7 OTHER THERAPEUTIC AREAS 68

    10 DRUG DISCOVERY SERVICES MARKET, BY REGION 69

    10.1 INTRODUCTION 70

    10.2 NORTH AMERICA 71

    10.2.1 US 75

    10.2.2 CANADA 78

    10.3 EUROPE 82

    10.3.1 GERMANY 87

    10.3.2 UK 90

    10.3.3 FRANCE 92

    10.3.4 REST OF EUROPE (ROE) 95

    10.4 ASIA PACIFIC (APAC) 98

    10.4.1 CHINA 102

    10.4.2 JAPAN 105

    10.4.3 INDIA 107

    10.4.4 REST OF ASIA PACIFIC (ROAPAC) 110

    10.5 REST OF THE WORLD (ROW) 112

    11 COMPETITIVE LANDSCAPE 115

    11.1 MARKET SHARE ANALYSIS 115

    12 COMPANY PROFILES 116

    (Overview, Strength of Product Portfolio, Business Strategy Excellence, Products Offering, and Recent Developments)*

    12.1 THERMO FISHER SCIENTIFIC 116

    12.2 MERCK 120

    12.3 GE HEALTHCARE 123

    12.4 ALBANY MOLECULAR RESEARCH, INC. (AMRI) 126

    12.5 CHARLES RIVER LABORATORIES INTERNATIONAL 130

    12.6 EVOTEC 134

    12.7 PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC. (PPD) 140

    12.8 JUBILANT BIOSYS 142

    12.9 COVANCE 145

    12.10 GENSCRIPT BIOTECH CORPORATION 148

    12.11 AURIGENE DISCOVERY TECHNOLOGIES 150

    12.12 WUXI APPTEC 153

    12.13 SYNGENE 156

    *Details on Overview, Strength of Product Portfolio, Business Strategy Excellence, Products Offering, and Recent Developments might not be captured in case of unlisted companies.

    13 APPENDIX 159

    13.1 INDUSTRY INSIGHTS 159

    13.2 DISCUSSION GUIDE 160

    13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 163

    13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 165

    13.5 AVAILABLE CUSTOMIZATIONS 166

    13.6 RELATED REPORTS 167

    13.7 AUTHOR DETAILS 168

List Of Tables
in Drug Discovery Services Market by Process (Target Selection, Hit-to-Lead Identification, Lead Optimization), Type (Medicinal Chemistry, Biology Services, DMPK), Drug Type (Small Molecules, Biologics), Therapeutic Areas (Oncology, Neurology) - Forecast to 2022

LIST OF TABLES


TABLE 1 TOTAL GLOBAL PHARMACEUTICAL R&D SPENDING, 2012 TO 2022 (USD BILLION) 37

TABLE 2 R&D SPENDING, PHRMA MEMBER-COMPANIES (USD BILLION) 37

TABLE 3 ACTIVITIES OUTSOURCED IN THE PHARMACEUTICAL INDUSTRY (2014 VS. 2015) 38

TABLE 4 RESEARCH PROJECTS FUNDED BY IRDIRC BODIES 39

TABLE 5 AVERAGE COST OF DRUGS APPROVED BY YEAR 41

TABLE 6 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2015–2022 (USD MILLION) 45

TABLE 7 TARGET SELECTION MARKET, BY REGION, 2015–2022 (USD MILLION) 46

TABLE 8 TARGET VALIDATION MARKET, BY REGION, 2015–2022 (USD MILLION) 47

TABLE 9 HIT-TO-LEAD IDENTIFICATION PROCESS MARKET, BY REGION,

2015–2022 (USD MILLION) 48

TABLE 10 LEAD OPTIMIZATION MARKET, BY REGION, 2015–2022 (USD MILLION) 49

TABLE 11 CANDIDATE VALIDATION MARKET, BY REGION, 2015–2022 (USD MILLION) 50

TABLE 12 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION) 52

TABLE 13 MEDICINAL CHEMISTRY SERVICES MARKET, BY REGION,

2015–2022 (USD MILLION) 53

TABLE 14 BIOLOGY SERVICES MARKET, BY REGION, 2015–2022 (USD MILLION) 54

TABLE 15 DRUG METABOLISM AND PHARMACOKINETICS SERVICES MARKET, BY REGION, 2015–2022 (USD MILLION) 55

TABLE 16 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2015–2022 (USD MILLION) 57

TABLE 17 SMALL MOLECULES MARKET, BY REGION, 2015–2022 (USD MILLION) 58

TABLE 18 BIOLOGICS MARKET, BY REGION, 2015–2022 (USD MILLION) 59

TABLE 19 GLOBAL NUMBER OF CLINICAL TRIALS IN DIFFERENT THERAPEUTIC AREAS, 2016 61

TABLE 20 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,

2015–2022 (USD MILLION) 62

TABLE 21 DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY REGION,

2015–2022 (USD MILLION) 64

TABLE 22 DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGY, BY REGION,

2015–2022 (USD MILLION) 65

TABLE 23 DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES,

BY REGION, 2015–2022 (USD MILLION) 66

TABLE 24 DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISEASES, BY REGION, 2015–2022 (USD MILLION) 66

TABLE 25 DRUG DISCOVERY SERVICES MARKET FOR DIABETES, BY REGION,

2015–2022 (USD MILLION) 67

TABLE 26 DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS,

BY REGION, 2015–2022 (USD MILLION) 68

TABLE 27 DRUG DISCOVERY SERVICES MARKET, BY REGION, 2015–2022 (USD MILLION) 71

TABLE 28 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY,

2015–2022 (USD MILLION) 73

TABLE 29 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,

2015–2022 (USD MILLION) 73

TABLE 30 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE,

2015–2022 (USD MILLION) 74

TABLE 31 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,

2015–2022 (USD MILLION) 74

TABLE 32 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2015–2022 (USD MILLION) 75

TABLE 33 US: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,

2015–2022 (USD MILLION) 76

TABLE 34 US: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION) 77

TABLE 35 US: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,

2015–2022 (USD MILLION) 77

TABLE 36 US: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,

2015–2022 (USD MILLION) 78

TABLE 37 CANADA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,

2015–2022 (USD MILLION) 80

TABLE 38 CANADA: DRUG DISCOVERY SERVICES MARKET, BY TYPE,

2015–2022 (USD MILLION) 80

TABLE 39 CANADA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,

2015–2022 (USD MILLION) 81

TABLE 40 CANADA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,

2015–2022 (USD MILLION) 81

TABLE 41 EUROPE: PHARMACEUTICAL R&D EXPENDITURE, BY COUNTRY, 2012 & 2014 83

TABLE 42 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY/REGION,

2015 –2022 (USD MILLION) 85

TABLE 43 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,

2015–2022 (USD MILLION) 85

TABLE 44 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE,

2015–2022 (USD MILLION) 86

TABLE 45 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,

2015–2022 (USD MILLION) 86

TABLE 46 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,

2015–2022 (USD MILLION) 87

TABLE 47 PHARMACEUTICAL R&D INVESTMENTS IN GERMANY (2010–2014) 88

TABLE 48 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,

2015–2022 (USD MILLION) 88

TABLE 49 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY TYPE,

2015–2022 (USD MILLION) 88

TABLE 50 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,

2015–2022 (USD MILLION) 89

TABLE 51 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,

2015–2022 (USD MILLION) 89

TABLE 52 UK: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,

2015–2022 (USD MILLION) 90

TABLE 53 UK: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION) 91

TABLE 54 UK: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,

2015–2022 (USD MILLION) 91

TABLE 55 UK: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,

2015–2022 (USD MILLION) 92

TABLE 56 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,

2015–2022 (USD MILLION) 93

TABLE 57 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY TYPE,

2015–2022 (USD MILLION) 93

TABLE 58 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,

2015–2022 (USD MILLION) 94

TABLE 59 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,

2015–2022 (USD MILLION) 94

TABLE 60 PHARMACEUTICAL R&D INVESTMENTS IN ITALY, 2009–2014 95

TABLE 61 PHARMACEUTICAL R&D EXPENDITURE IN BELGIUM, 2010–2014 96

TABLE 62 PHARMACEUTICAL PRODUCTION AND R&D EXPENDITURE IN DENMARK,

2012–2014 96

TABLE 63 ROE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,

2015–2022 (USD MILLION) 96

TABLE 64 ROE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION) 97

TABLE 65 ROE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,

2015–2022 (USD MILLION) 97

TABLE 66 ROE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,

2015–2022 (USD MILLION) 98

TABLE 67 TOTAL NUMBER OF CLINICAL TRIALS IN APAC, BY THERAPEUTIC AREA, 2016 98

TABLE 68 APAC: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY/REGION,

2015–2022 (USD MILLION) 100

TABLE 69 APAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,

2015–2022 (USD MILLION) 100

TABLE 70 APAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION) 101

TABLE 71 APAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,

2015–2022 (USD MILLION) 101

TABLE 72 APAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,

2015–2022 (USD MILLION) 102

TABLE 73 CHINA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,

2015–2022 (USD MILLION) 103

TABLE 74 CHINA: DRUG DISCOVERY SERVICES MARKET, BY TYPE,

2015–2022 (USD MILLION) 103

TABLE 75 CHINA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,

2015–2022 (USD MILLION) 104

TABLE 76 CHINA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,

2015–2022 (USD MILLION) 104

TABLE 77 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,

2015–2022 (USD MILLION) 105

TABLE 78 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY TYPE,

2015–2022 (USD MILLION) 106

TABLE 79 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,

2015–2022 (USD MILLION) 106

TABLE 80 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,

2015–2022 (USD MILLION) 107

TABLE 81 INDIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,

2015–2022 (USD MILLION) 108

TABLE 82 INDIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION) 108

TABLE 83 INDIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,

2015–2022 (USD MILLION) 109

TABLE 84 INDIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,

2015–2022 (USD MILLION) 109

TABLE 85 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,

2015–2022 (USD MILLION) 110

TABLE 86 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE,

2015–2022 (USD MILLION) 110

TABLE 87 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,

2015–2022 (USD MILLION) 111

TABLE 88 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,

2015–2022 (USD MILLION) 111

TABLE 89 ROW: DRUG DISCOVERY SERVICES MARKET, BY PROCESS,

2015–2022 (USD MILLION) 112

TABLE 90 ROW: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION) 113

TABLE 91 ROW: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,

2015–2022 (USD MILLION) 113

TABLE 92 ROW: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,

2015–2022 (USD MILLION) 114

List Of Figures, Charts and Diagrams
in Drug Discovery Services Market by Process (Target Selection, Hit-to-Lead Identification, Lead Optimization), Type (Medicinal Chemistry, Biology Services, DMPK), Drug Type (Small Molecules, Biologics), Therapeutic Areas (Oncology, Neurology) - Forecast to 2022

LIST OF FIGURES


FIGURE 1 GLOBAL DRUG DISCOVERY SERVICES MARKET 17

FIGURE 2 RESEARCH DESIGN 19

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,

DESIGNATION, AND REGION 22

FIGURE 4 DATA TRIANGULATION METHODOLOGY 25

FIGURE 5 DRUG DISCOVERY SERVICES MARKET, BY PROCESS,

2017 VS. 2022 (USD BILLION) 27

FIGURE 6 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2017 VS. 2022 (USD BILLION) 28

FIGURE 7 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,

2017 VS. 2022 (USD BILLION) 29

FIGURE 8 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,

2017 VS. 2022 (USD BILLION) 30

FIGURE 9 DRUG DISCOVERY SERVICES MARKET, BY REGION, 2017 VS. 2022 (USD BILLION) 31

FIGURE 10 INCREASING DEMAND FOR OUTSOURCING OF ANALYTICAL TESTING AND CLINICAL TRIAL SERVICES TO DRIVE MARKET GROWTH 32

FIGURE 11 ONCOLOGY SEGMENT TO COMMAND THE LARGEST MARKET SHARE OF EUROPEAN DRUG DISCOVERY SERVICES MARKET IN 2017 33

FIGURE 12 MEDICINAL CHEMISTRY TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD (2017-2022) 34

FIGURE 13 ASIA PACIFIC TO REGISTER THE HIGHEST CAGR BETWEEN 2017 & 2022 35

FIGURE 14 DRUG DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES 36

FIGURE 15 NUMBER OF REGISTERED STUDIES (2000-2017) 40

FIGURE 16 HIT-TO-LEAD IDENTIFICATION TO HOLD LARGEST MARKET SHARE IN 2017 45

FIGURE 17 MEDICINAL CHEMISTRY SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE DRUG DISCOVERY SERVICES MARKET 52

FIGURE 18 SMALL MOLECULES—THE LARGEST SEGMENT IN THE DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPES 57

FIGURE 19 ONCOLOGY SEGMENT TO HOLD THE LARGEST SHARE IN DRUG DISCOVERY SERVICES MARKET IN 2017 61

FIGURE 20 TOTAL NUMBER OF CLINICAL TRIALS FOR ONCOLOGY (2016) 63

FIGURE 21 GEOGRAPHIC SNAPSHOT (2016): APAC MARKETS ARE EMERGING AS NEW GROWTH HOTSPOTS 70

FIGURE 22 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET SNAPSHOT 72

FIGURE 23 PHARMACEUTICAL R&D EXPENDITURE IN THE US (1990-2014) 76

FIGURE 24 TOTAL CANADIAN PHARMACEUTICAL TRADE (2004–2016) (USD BILLION) 79

FIGURE 25 YEARLY EMPLOYMENT IN MANUFACTURING PORTION OF PHARMACEUTICAL SECTOR (2005–2016) 79

FIGURE 26 PHARMACEUTICAL R&D EXPENDITURE IN EUROPE (2010–2014) 82

FIGURE 27 EUROPE: DRUG DISCOVERY SERVICES MARKET SNAPSHOT 84

FIGURE 28 APAC: DRUG DISCOVERY SERVICES MARKET SNAPSHOT 99

FIGURE 29 DRUG DISCOVERY SERVICES MARKET: MARKET SHARE (2016) 115

FIGURE 30 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2016) 116

FIGURE 31 MERCK: COMPANY SNAPSHOT (2016) 120

FIGURE 32 GE HEALTHCARE: COMPANY SNAPSHOT (2016) 123

FIGURE 33 ALBANY MOLECULAR RESEARCH, INC.: COMPANY SNAPSHOT (2016) 126

FIGURE 34 CHARLES RIVER LABORATORIES INTERNATIONAL: COMPANY SNAPSHOT (2016) 130

FIGURE 35 EVOTEC: COMPANY SNAPSHOT (2016) 134

FIGURE 36 JUBILANT BIOSYS: COMPANY SNAPSHOT (2016) 142

FIGURE 37 LABCORP: COMPANY SNAPSHOT (2016) 145

FIGURE 38 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2016) 148

FIGURE 39 SYNGENE: COMPANY SNAPSHOT (2016) 156

Additional Details

Publisher

MarketsandMarkets

Publisher Information

Reference

139339 | PH 5682

Number of Pages

170

Report Format

PDF

MarketsandMarkets Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Orphan Drug Commercial Models: Sustaining the rare disease business
IntroductionChoosing the right commercial model for orphan drug successThe societal and commercial a...
01 May 2016 by FirstWord Pharma USD $695 More Info
Pay-for-Performance and Drug Pricing: Impact and Response of Pharma [2016]
IntroductionThe pay for performance agenda gathers pace as US payers rebel the cost of drugs.Pharma ...
01 Mar 2016 by FirstWord Pharma USD $695 More Info
Innovations in Drug Pricing and Reimbursement (2016)
IntroductionIs the drug pricing bubble about to burst?Drug costs are becoming unaffordable and draco...
01 Feb 2016 by FirstWord Pharma USD $2,195 More Info
Drug Delivery - Innovations, trends, and their impact on pharma
IntroductionWhy you need Drug Delivery - Innovations, trends, and their impact on pharmaRevolutionar...
01 Nov 2015 by FirstWord Pharma USD $2,195 More Info
Physician Views: Which companies excel in diabetes drug marketing and why?
Scope With both the insulin and non-insulin segments of the diabetes market expected to become more ...
01 May 2015 by FirstWord Pharma USD $695 More Info
Trends and Innovations in Drug Pricing
IntroductionFirstWord’s Trends and Innovations in Drug Pricing report dissects international trends ...
01 Jan 2015 by FirstWord Pharma USD $695 More Info
Orphan Drug Market Access: Payer Insights on the Present and Future
IntroductionOrphan Drug Market Access: Payer Insights on the Present and Future is a report that exa...
14 Oct 2014 by FirstWord Pharma USD $695 More Info
Physician Views: With drug developers on the brink of Phase III for NASH, how large is the actual market opportunity?
Scope While no drugs are approved for non-alcoholic steatohepatitis (NASH), at least eight agents ha...
04 Aug 2014 by FirstWord Pharma USD $695 More Info
Physician Views: As Tecfidera approaches a critical juncture in Europe, how are neurologist perceptions towards Biogen Idec's MS drug shaping up?
ScopeSales of Biogen Idec’s multiple sclerosis therapy Tecfidera may continue to exceed initial expe...
01 Nov 2013 by FirstWord Pharma USD $695 More Info
Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
01 Jun 2013 by FirstWord Pharma USD $695 More Info

This report is published by MarketsandMarkets

Download Free Report Summary PDF

Drug Discovery Services Market by Process (Target Selection, Hit-to-Lead Identification, Lead Optimization), Type (Medicinal Chemistry, Biology Services, DMPK), Drug Type (Small Molecules, Biologics), Therapeutic Areas (Oncology, Neurology) - Forecast to 2022 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...